Fisher Asset Management LLC Purchases 30,612 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Fisher Asset Management LLC grew its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 18.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 198,696 shares of the biopharmaceutical company’s stock after acquiring an additional 30,612 shares during the period. Fisher Asset Management LLC owned about 0.21% of Ultragenyx Pharmaceutical worth $4,570,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of RARE. Aquatic Capital Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 79.1% during the 3rd quarter. Aquatic Capital Management LLC now owns 191,458 shares of the biopharmaceutical company’s stock worth $5,759,000 after buying an additional 84,559 shares during the last quarter. Thornburg Investment Management Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the 3rd quarter worth about $2,083,000. Aberdeen Group plc lifted its stake in shares of Ultragenyx Pharmaceutical by 94.3% during the 3rd quarter. Aberdeen Group plc now owns 973,656 shares of the biopharmaceutical company’s stock worth $29,288,000 after buying an additional 472,600 shares during the last quarter. WCM Investment Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 36.9% during the 3rd quarter. WCM Investment Management LLC now owns 288,109 shares of the biopharmaceutical company’s stock worth $8,747,000 after buying an additional 77,640 shares during the last quarter. Finally, Rafferty Asset Management LLC lifted its stake in shares of Ultragenyx Pharmaceutical by 93.0% during the 3rd quarter. Rafferty Asset Management LLC now owns 156,484 shares of the biopharmaceutical company’s stock worth $4,707,000 after buying an additional 75,388 shares during the last quarter. Institutional investors own 97.67% of the company’s stock.

Analysts Set New Price Targets

RARE has been the subject of several analyst reports. HC Wainwright dropped their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. Barclays dropped their price objective on shares of Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. Wedbush dropped their price objective on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Finally, Morgan Stanley raised their target price on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a report on Thursday, April 16th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $59.56.

Ultragenyx Pharmaceutical Stock Down 0.6%

RARE stock opened at $23.26 on Friday. The firm has a market cap of $2.29 billion, a P/E ratio of -3.81 and a beta of 0.39. The company’s 50-day moving average price is $23.36 and its two-hundred day moving average price is $25.84. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.49) by ($0.35). The company had revenue of $136.00 million for the quarter, compared to the consensus estimate of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The company’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.57) earnings per share. Equities analysts predict that Ultragenyx Pharmaceutical Inc. will post -4.62 EPS for the current year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, CFO Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $24.90, for a total transaction of $116,606.70. Following the sale, the chief financial officer directly owned 110,342 shares of the company’s stock, valued at approximately $2,747,515.80. The trade was a 4.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Theodore Alan Huizenga sold 1,632 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $22.80, for a total transaction of $37,209.60. Following the sale, the chief accounting officer directly owned 48,670 shares in the company, valued at $1,109,676. This trade represents a 3.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 117,262 shares of company stock worth $2,687,403 in the last ninety days. Insiders own 5.20% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.